陰圧閉鎖療法市場は、2025年の27億6000万ドルから2030年までに38億4000万ドルに成長し、予測期間中のCAGRは6.9%のCAGRになると予想されます。陰圧閉鎖療法市場における著名なプレーヤーには、Solventum(米国)、Smith+Nephew(英国)、Cardinal Health(米国)、Mölnlycke AB(スウェーデン)、Convatec Group PLC(英国)、PAUL HARTMANN AG(ドイツ)、Avery Dennison Corporation(米国)、BenQ Materials Corporation(台湾)、Double Medical Technology Inc.(中国)、Advanced Oxygen Therapy Inc.(米国)、Carilex Medical(台湾)が含まれます。
目次
TABLE OF CONTENTS
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.3 STUDY SCOPE
1.3.1 MARKETS COVERED AND REGIONAL SCOPE
1.3.2 INCLUSIONS AND EXCLUSIONS
1.3.3 YEARS CONSIDERED
1.4 CURRENCY CONSIDERED
1.5 STAKEHOLDERS
1.6 SUMMARY OF CHANGES
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
2.1.1 SECONDARY DATA
2.1.1.1 Key data from secondary sources
2.1.2 PRIMARY DATA
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Key data from primary sources
2.1.2.4 Breakdown of primary interviews
2.2 MARKET SIZE ESTIMATION
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
2.2.1.2 Approach 2: Presentations of companies and primary interviews
2.2.1.3 Approach 3: Primary interviews
2.2.1.4 Growth forecast
2.2.1.5 CAGR projections
2.2.2 TOP-DOWN APPROACH
2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
2.4 RESEARCH ASSUMPTIONS
2.4.1 STUDY-RELATED ASSUMPTIONS
2.4.2 PARAMETRIC ASSUMPTIONS
2.4.3 GROWTH RATE ASSUMPTIONS
2.5 RESEARCH LIMITATIONS
2.6 RISK ASSESSMENT
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 NEGATIVE PRESSURE WOUND THERAPY MARKET OVERVIEW
4.2 ASIA PACIFIC NEGATIVE PRESSURE WOUND THERAPY MARKET, BY END USER AND COUNTRY
4.3 NEGATIVE PRESSURE WOUND THERAPY MARKET, BY KEY COUNTRY
4.4 NEGATIVE PRESSURE WOUND THERAPY MARKET, REGIONAL MIX, 2025 VS. 2030
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
5.2.1 DRIVERS
5.2.1.1 Booming geriatric population
5.2.1.2 Increasing cases of traumatic injuries
5.2.1.3 Growing prevalence of chronic diseases
5.2.1.4 Rising incidence of burn injuries
5.2.1.5 Favorable government and industry initiatives and reimbursement policies
5.2.2 RESTRAINTS
5.2.2.1 High cost of negative pressure wound therapy devices
5.2.2.2 Risks associated with use of negative pressure wound therapy products
5.2.3 OPPORTUNITIES
5.2.3.1 Growth opportunities in emerging economies
5.2.3.2 Increasing use of simplified single-use devices
5.2.4 CHALLENGES
5.2.4.1 Availability of alternative therapies
5.2.4.2 Limited awareness among healthcare providers
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
5.4 PRICING ANALYSIS
5.4.1 AVERAGE SELLING PRICE TREND, BY PRODUCT
5.4.2 AVERAGE SELLING PRICE TREND, BY KEY PLAYER
5.4.3 AVERAGE SELLING PRICE TREND, BY REGION
5.5 VALUE CHAIN ANALYSIS
5.6 SUPPLY CHAIN ANALYSIS
5.7 ECOSYSTEM ANALYSIS
5.8 INVESTMENT AND FUNDING SCENARIO
5.9 TECHNOLOGY ANALYSIS
5.9.1 KEY TECHNOLOGIES
5.9.1.1 Vacuum-assisted Closure (VAC) Therapy
5.9.2 COMPLEMENTARY TECHNOLOGIES
5.9.2.1 Topical Oxygen Therapy
5.9.3 ADJACENT TECHNOLOGIES
5.9.3.1 Hyperbaric Oxygen Therapy
5.10 PATENT ANALYSIS
5.11 TRADE ANALYSIS
5.11.1 IMPORT DATA (HS CODE 901890)
5.11.2 EXPORT DATA (HS CODE 901890)
5.12 KEY CONFERENCES AND EVENTS, 2025-2026
5.13 CASE STUDY ANALYSIS
5.13.1 CASE STUDY 1: COMPLEX WOUND HEALING WITH TOPICAL NEGATIVE PRESSURE WOUND THERAPY
5.13.2 CASE STUDY 2: NECROTIZING FASCIITIS MANAGED WITH NEGATIVE PRESSURE WOUND THERAPY FOR BETTER WOUND CLOSURE
5.13.3 CASE STUDY 3: TREATMENT OF HARD-TO-HEAL WOUNDS WITH PORTABLE NEGATIVE PRESSURE WOUND THERAPY
5.14 REGULATORY LANDSCAPE
5.14.1 REGULATORY ANALYSIS
5.14.1.1 North America
5.14.1.1.1 US
5.14.1.1.2 Canada
5.14.1.2 Europe
5.14.1.2.1 Germany
5.14.1.2.2 UK
5.14.1.2.3 France
5.14.1.3 Asia Pacific
5.14.1.3.1 China
5.14.1.3.2 Japan
5.14.1.3.3 India
5.14.1.4 Latin America
5.14.1.5 Middle East
5.14.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.14.2.1 North America
5.14.2.2 Europe
5.14.2.3 Asia Pacific
5.14.2.4 Latin America
5.14.2.5 Rest of the World
5.15 PORTER'S FIVE FORCES ANALYSIS
5.15.1 BARGAINING POWER OF SUPPLIERS
5.15.2 BARGAINING POWER OF BUYERS
5.15.3 THREAT OF NEW ENTRANTS
5.15.4 THREAT OF SUBSTITUTES
5.15.5 INTENSITY OF COMPETITIVE RIVALRY
5.16 KEY STAKEHOLDERS AND BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
5.16.2 BUYING CRITERIA
5.17 IMPACT OF AI ON NEGATIVE PRESSURE WOUND THERAPY MARKET
5.17.1 INTRODUCTION
5.17.2 MARKET POTENTIAL OF AI IN NEGATIVE PRESSURE WOUND THERAPY MARKET
5.17.3 AI USE CASES
5.17.4 KEY COMPANIES IMPLEMENTING AI
5.17.5 FUTURE OF AI IN NEGATIVE PRESSURE WOUND THERAPY MARKET
5.18 IMPACT OF US TARIFF REGULATION ON NEGATIVE PRESSURE WOUND THERAPY MARKET
5.18.1 INTRODUCTION
5.18.2 KEY TARIFF RATES
5.18.3 PRICE IMPACT ANALYSIS
5.18.4 KEY IMPACT ON COUNTRY/REGION
5.18.4.1 North America
5.18.4.2 Europe
5.18.4.3 Asia Pacific
5.18.5 IMPACT ON END-USE INDUSTRIES
5.18.5.1 Hospitals
6 NEGATIVE PRESSURE WOUND THERAPY MARKET, BY PRODUCT TYPE
6.1 INTRODUCTION
6.2 CONVENTIONAL NPWT DEVICES
6.2.1 RISING FOCUS ON EFFECTIVE WOUND MANAGEMENT TO EXPEDITE GROWTH
6.3 SINGLE-USE NPWT DEVICES
6.3.1 INCREASING ADOPTION OF SINGLE-USE DEVICES IN HOME HEALTHCARE TO PROMOTE GROWTH
6.4 NPWT ACCESSORIES & CONSUMABLES
6.4.1 GROWING PREVALENCE OF CHRONIC WOUNDS TO DRIVE MARKET
7 NEGATIVE PRESSURE WOUND THERAPY MARKET, BY WOUND TYPE
7.1 INTRODUCTION
7.2 BURNS AND SURGICAL & OPEN WOUNDS
7.2.1 HIGH INCIDENCE OF BURN INJURIES IN LOW AND MIDDLE-INCOME COUNTRIES TO AID GROWTH
7.3 PRESSURE ULCERS
7.3.1 INCREASING AGING POPULATION WORLDWIDE TO AUGMENT GROWTH
7.4 DIABETIC FOOT ULCERS
7.4.1 INCREASE PREVALENCE OF DIABETES TO STIMULATE GROWTH
7.5 VENOUS LEG ULCERS
7.5.1 RISING PREVALENCE OF OBESITY TO CONTRIBUTE TO GROWTH
7.6 TRAUMATIC WOUNDS
7.6.1 GROWING INCIDENCE OF TRAUMATIC INJURIES TO BOOST MARKET
8 NEGATIVE PRESSURE WOUND THERAPY MARKET, BY END USER
8.1 INTRODUCTION
8.2 HOSPITALS
8.2.1 RISING NUMBER OF SURGERIES TO ACCELERATE GROWTH
8.3 HOME CARE SETTINGS
8.3.1 INCREASING HEALTHCARE EXPENDITURE TO SPEED UP GROWTH
8.4 OTHER END USERS
9 NEGATIVE PRESSURE WOUND THERAPY MARKET, BY REGION
9.1 INTRODUCTION
9.2 NORTH AMERICA
9.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
9.2.2 US
9.2.2.1 Rising regulatory approvals and favorable reimbursement policies to stimulate growth
9.2.3 CANADA
9.2.3.1 Increasing prevalence of diabetes to support growth
9.3 EUROPE
9.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
9.3.2 UK
9.3.2.1 Increase in research & development activities to aid growth
9.3.3 GERMANY
9.3.3.1 Growing prevalence of hospital-acquired infections to propel market
9.3.4 FRANCE
9.3.4.1 Rise in healthcare budget to spur growth
9.3.5 ITALY
9.3.5.1 Increasing national healthcare funding to favor growth
9.3.6 SPAIN
9.3.6.1 Increasing number of surgical procedures to promote growth
9.3.7 RUSSIA
9.3.7.1 Escalating diabetes issue to drive market
9.3.8 REST OF EUROPE
9.4 ASIA PACIFIC
9.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
9.4.2 CHINA
9.4.2.1 Increasing incidence of diabetic foot ulcers to encourage growth
9.4.3 JAPAN
9.4.3.1 Evolving healthcare delivery and infrastructure landscape to fuel market
9.4.4 INDIA
9.4.4.1 Booming medical tourism to speed up growth
9.4.5 AUSTRALIA
9.4.5.1 Growing focus on diabetes management to drive market
9.4.6 SOUTH KOREA
9.4.6.1 Increasing awareness and focus on advanced wound care therapies to facilitate growth
9.4.7 SINGAPORE
9.4.7.1 Increasing healthcare spending to sustain growth
9.4.8 REST OF ASIA PACIFIC
9.5 LATIN AMERICA
9.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
9.5.2 BRAZIL
9.5.2.1 Free healthcare services to bolster growth
9.5.3 MEXICO
9.5.3.1 Expanding hospital infrastructure to aid growth
9.5.4 REST OF LATIN AMERICA
9.6 MIDDLE EAST & AFRICA
9.6.1 GROWING DEMAND FOR HEALTHCARE FACILITIES TO DRIVE MARKET
9.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW
10.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2024
10.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN NEGATIVE PRESSURE WOUND THERAPY MARKET
10.3 REVENUE ANALYSIS, 2022-2024
10.4 MARKET SHARE ANALYSIS, 2024
10.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
10.5.1 STARS
10.5.2 EMERGING LEADERS
10.5.3 PERVASIVE PLAYERS
10.5.4 PARTICIPANTS
10.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
10.5.5.1 Company footprint
10.5.5.2 Region footprint
10.5.5.3 Product type footprint
10.5.5.4 Wound type footprint
10.5.5.5 End-user footprint
10.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
10.6.1 PROGRESSIVE COMPANIES
10.6.2 RESPONSIVE COMPANIES
10.6.3 DYNAMIC COMPANIES
10.6.4 STARTING BLOCKS
10.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
10.6.5.1 Detailed list of key startups/SMEs
10.6.5.2 Competitive benchmarking of key startups/SMEs
10.7 COMPANY VALUATION AND FINANCIAL METRICS
10.7.1 COMPANY VALUATION
10.7.2 FINANCIAL METRICS
10.8 BRAND/PRODUCT COMPARISON
10.9 COMPETITIVE SCENARIO
10.9.1 PRODUCT LAUNCHES AND APPROVALS
10.9.2 DEALS
10.9.3 EXPANSIONS
10.9.4 OTHER DEVELOPMENTS
11 COMPANY PROFILES
11.1 KEY PLAYERS
11.1.1 SOLVENTUM
11.1.1.1 Business overview
11.1.1.2 Products offered
11.1.1.3 Recent developments
11.1.1.3.1 Product launches and approvals
11.1.1.3.2 Other developments
11.1.1.4 MnM view
11.1.1.4.1 Key strengths
11.1.1.4.2 Strategic choices
11.1.1.4.3 Weaknesses and competitive threats
11.1.2 SMITH+NEPHEW
11.1.2.1 Business overview
11.1.2.2 Products offered
11.1.2.3 Recent developments
11.1.2.3.1 Product launches and approvals
11.1.2.3.2 Deals
11.1.2.3.3 Expansions
11.1.2.4 MnM view
11.1.2.4.1 Key strengths
11.1.2.4.2 Strategic choices
11.1.2.4.3 Weaknesses and competitive threats
11.1.3 CARDINAL HEALTH
11.1.3.1 Business overview
11.1.3.2 Products offered
11.1.3.3 Recent developments
11.1.3.3.1 Deals
11.1.3.3.2 Expansions
11.1.3.4 MnM view
11.1.3.4.1 Key strengths
11.1.3.4.2 Strategic choices
11.1.3.4.3 Weaknesses and competitive threats
11.1.4 MOLNLYCKE AB
11.1.4.1 Business overview
11.1.4.2 Products offered
11.1.4.3 Recent developments
11.1.4.3.1 Deals
11.1.4.4 MnM view
11.1.4.4.1 Key strengths
11.1.4.4.2 Strategic choices
11.1.4.4.3 Weaknesses and competitive threats
11.1.5 CONVATEC GROUP PLC
11.1.5.1 Business overview
11.1.5.2 Products offered
11.1.5.3 Recent developments
11.1.5.3.1 Deals
11.1.5.4 MnM view
11.1.5.4.1 Key strengths
11.1.5.4.2 Strategic choices
11.1.5.4.3 Weaknesses and competitive threats
11.1.6 PAUL HARTMANN AG
11.1.6.1 Business overview
11.1.6.2 Products offered
11.1.6.3 Recent developments
11.1.6.3.1 Deals
11.1.7 AVERY DENNISON CORPORATION
11.1.7.1 Business overview
11.1.7.2 Products offered
11.1.7.3 Recent developments
11.1.7.3.1 Deals
11.1.7.3.2 Expansions
11.1.8 BENQ MATERIALS CORPORATION
11.1.8.1 Business overview
11.1.8.2 Products offered
11.1.8.3 Recent developments
11.1.8.3.1 Deals
11.1.8.3.2 Other developments
11.1.9 ADVANCED OXYGEN THERAPY INC.
11.1.9.1 Business overview
11.1.9.2 Products offered
11.1.9.3 Recent developments
11.1.9.3.1 Product launches and approvals
11.2 OTHER PLAYERS
11.2.1 DOUBLE MEDICAL TECHNOLOGY INC.
11.2.2 CARILEX MEDICAL
11.2.3 DEROYAL INDUSTRIES, INC.
11.2.4 LOHMANN & RAUSCHER GMBH & CO. KG
11.2.5 MEDAXIS LLC
11.2.6 GENADYNE BIOTECHNOLOGIES, INC.
11.2.7 DIRECT HEALTHCARE GROUP
11.2.8 ALLEVA MEDICAL
11.2.9 CORK MEDICAL, LLC
11.2.10 PENSAR MEDICAL
11.2.11 HAROMED
11.2.12 GUANGZHOU RAINHOME PHARM & TECH CO., LTD.
11.2.13 GUARD MEDICAL
11.2.14 DATT MEDIPRODUCTS PRIVATE LIMITED
11.2.15 KORAZON MEDICAL DEVICES PRIVATE LIMITED
11.2.16 TRIAGE MEDITECH PVT. LTD.
12 APPENDIX
12.1 DISCUSSION GUIDE
12.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
12.3 CUSTOMIZATION OPTIONS
12.4 RELATED REPORTS
12.5 AUTHOR DETAILS
